RxDoctor Payments Data

Christopher Shelby, MD

Family Medicine · Biloxi, MSNPI 1851333009

Payments from drug & device makers

$8,284in general payments, 2019–2025

Across 570 payments — averaging $14.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$927
  • AstraZeneca$771
  • Astellas Pharma US Inc$474
  • Novo Nordisk$469
  • Amgen$454
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$8,09698%
  • Education$1882%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,284 in reported general payments places this provider in the 90th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$253,860
Medicare patients
590
Services billed
4,572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$116,979
EliquisApixaban69$59,765
JanuviaSitagliptin Phosphate44$41,627
XareltoRivaroxaban23$38,522
JardianceEmpagliflozin25$37,068
MounjaroTirzepatide20$32,507
Breo ElliptaFluticasone/Vilanterol46$29,360
Spiriva RespimatTiotropium Bromide13$14,855
InvokanaCanagliflozin12$12,520
Tresiba Flextouch U-100Insulin Degludec21$11,877
Synjardy XrEmpagliflozin/Metformin Hcl19$10,778
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$10,278
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,186
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$7,026
MyrbetriqMirabegron11$6,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$469$116,97973 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Synjardy Xr$139$62,70157 claims
PfizerEliquis$927$59,76569 claims
Johnson & JohnsonXarelto, Invokana$270$51,04135 claims
MerckJanuvia$81$41,62744 claims
GSKBreo Ellipta, Trelegy Ellipta$95$39,54662 claims
Lilly USA, LLCMounjaro$435$32,50720 claims
Astellas Pharma US IncMyrbetriq$474$6,34911 claims
AbbVieSynthroid$1,340$2,50743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Biloxi

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →